Dexcom (DXCM) is a publicly traded Healthcare sector company. As of August 24, 2026, DXCM trades at $91.07 with a market cap of $34.85B and a P/E ratio of 35.32. DXCM moved -1.39% today. Year to date, DXCM is +39.13%; over the trailing twelve months it is +14.54%. Its 52-week range spans $54.11 to $93.25. Analyst consensus is strong buy with an average price target of $93.24. Rallies surfaces DXCM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for DXCM combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $91.07 |
| Market Cap | $34.85B |
| P/E Ratio | 35.32 |
| EPS | $2.59 |
| Dividend Yield | 0.00% |
| 52-Week High | $93.25 |
| 52-Week Low | $54.11 |
| Volume | 2.11M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.97B |
| Net Income | $999.70M |
| Gross Margin | 62.47% |
19 analysts cover DXCM: 0 strong buy, 18 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $93.24.